Ger­many's Rentschler looks to build UK foot­print with five-year in­vest­ment in cell and gene ther­a­pies

Look­ing to add an­oth­er ca­pa­bil­i­ty to its ar­se­nal, Ger­man CD­MO Rentschler Bio­phar­ma will bump up its in­vest­ment in cell and gene ther­a­pies over the next five years through a new site at the Cell and Gene Ther­a­py Cat­a­pult in the UK.

Lo­cat­ed in Steve­nage, Eng­land, the site will al­low Rentschler to es­tab­lish the man­u­fac­tur­ing of vi­ral vec­tors for clin­i­cal sup­ply. The com­pa­ny ex­pects to be ready for cGMP man­u­fac­tur­ing by the first half of 2022 and will al­so es­tab­lish man­u­fac­tur­ing ca­pa­bil­i­ty in ad­vanced ther­a­py med­i­c­i­nal prod­ucts, in­clud­ing ade­no-as­so­ci­at­ed virus vec­tors for clin­i­cal tri­al sup­ply.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER